Abiopharma

🔍 Aslan Fred (Executive)

Company: Artiva Biotherapeutics, Inc. (ARTV)

Report Date: 2026-09-10

Detailed Transactions and Holdings:

• Acquired 45,000 shares of Common Stock (Direct)
  Date: 2026-09-10 | Code: A | equity_swap_involved: false | shares_owned_after: 1,494,765.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 155,000 shares of Employee Stock Option (Right to Buy) at $10.42 per share (Derivative)
  Date: 2026-09-10 | Code: A | Expires: 2036-09-09 | equity_swap_involved: false | shares_owned_after: 155,000.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan.
• F2: Beginning on September 8, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four-year period.